Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$3.0 - $5.49 $50,412 - $92,253
16,804 Added 123.2%
30,444 $96,000
Q2 2022

Aug 15, 2022

BUY
$3.13 - $12.25 $42,693 - $167,090
13,640 New
13,640 $47,000
Q1 2022

May 16, 2022

SELL
$9.54 - $14.26 $110,940 - $165,829
-11,629 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$7.34 - $10.25 $172,100 - $240,331
-23,447 Reduced 66.85%
11,629 $111,000
Q3 2021

Nov 15, 2021

BUY
$8.05 - $13.29 $162,432 - $268,165
20,178 Added 135.44%
35,076 $310,000
Q2 2021

Aug 16, 2021

SELL
$11.76 - $16.85 $35,797 - $51,291
-3,044 Reduced 16.97%
14,898 $183,000
Q1 2021

May 17, 2021

BUY
$14.21 - $25.3 $254,955 - $453,932
17,942 New
17,942 $286,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $30.6M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.